{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:29:09Z","timestamp":1780525749967,"version":"3.54.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1210498"],"award-info":[{"award-number":["OPP1210498"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-024-03474-3","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T03:35:13Z","timestamp":1725420913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antibacterial efficacy of mycobacteriophages against virulent Mycobacterium tuberculosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Sharumathi","family":"Jeyasankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeswanth Chakravarthy","family":"Kalapala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi Raj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachit","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"3474_CR1","doi-asserted-by":"crossref","unstructured":"Hershkovitz I, Donoghue HD, Minnikin DE, Besra GS, Lee OYC, Gernaey AM et al. Detection and Molecular Characterization of 9000-Year-Old Mycobacterium tuberculosis from a Neolithic Settlement in the Eastern Mediterranean. Ahmed N, editor. PLoS ONE. 2008;3(10):e3426.","DOI":"10.1371\/journal.pone.0003426"},{"key":"3474_CR2","unstructured":"Global Tuberculosis Report. 2023 [Internet]. [cited 2024 Feb 7]. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023"},{"issue":"4","key":"3474_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.plipres.2012.05.002","volume":"51","author":"JA Verschoor","year":"2012","unstructured":"Verschoor JA, Baird MS, Grooten J. Towards understanding the functional diversity of cell wall mycolic acids of Mycobacterium tuberculosis. Prog Lipid Res. 2012;51(4):325\u201339.","journal-title":"Prog Lipid Res"},{"issue":"1","key":"3474_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1128\/MMBR.00028-07","volume":"72","author":"EC Hett","year":"2008","unstructured":"Hett EC, Rubin EJ. Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev MMBR. 2008;72(1):126\u201356.","journal-title":"Microbiol Mol Biol Rev MMBR"},{"issue":"12","key":"3474_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/cmi.2017.88","volume":"14","author":"CH Liu","year":"2017","unstructured":"Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. Cell Mol Immunol. 2017;14(12):963\u201375.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"3474_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00018-016-2422-8","volume":"74","author":"JA Awuh","year":"2017","unstructured":"Awuh JA, Flo TH. Molecular basis of mycobacterial survival in macrophages. Cell Mol Life Sci. 2017;74(9):1625\u201348.","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"3474_CR7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41423-020-0502-z","volume":"17","author":"Q Chai","year":"2020","unstructured":"Chai Q, Wang L, Liu CH, Ge B. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cell Mol Immunol. 2020;17(9):901\u201313.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"3474_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/femsre\/fuz006","volume":"43","author":"C Bussi","year":"2019","unstructured":"Bussi C, Gutierrez MG. Mycobacterium tuberculosis infection of host cells in space and time. FEMS Microbiol Rev. 2019;43(4):341\u201361.","journal-title":"FEMS Microbiol Rev"},{"key":"3474_CR9","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update [Internet]. [cited 2023 Jul 4]. https:\/\/www.who.int\/publications-detail-redirect\/9789240063129"},{"issue":"2","key":"3474_CR10","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/S2213-2600(23)00426-5","volume":"12","author":"SM Labuda","year":"2024","unstructured":"Labuda SM, Seaworth B, Dasgupta S, Goswami ND. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. Lancet Respir Med. 2024;12(2):e5\u20136.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3474_CR11","doi-asserted-by":"publisher","first-page":"e00409","DOI":"10.1128\/Spectrum.00409-21","volume":"9","author":"H Xia","year":"2021","unstructured":"Xia H, Zheng Y, Liu D, Wang S, He W, Zhao B, et al. Strong increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis isolates in China, 2007 to 2013. Microbiol Spectr. 2021;9(3):e00409\u201321.","journal-title":"Microbiol Spectr"},{"issue":"2","key":"3474_CR12","doi-asserted-by":"publisher","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","volume":"4","author":"JS Mallick","year":"2022","unstructured":"Mallick JS, Nair P, Abbew ET, Van Deun A, Decroo T. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC-Antimicrob Resist. 2022;4(2):dlac029.","journal-title":"JAC-Antimicrob Resist"},{"issue":"1","key":"3474_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/ijmr.IJMR_1168_19","volume":"154","author":"R Nambiar","year":"2021","unstructured":"Nambiar R, Tornheim JA, Diricks M, Bruyne KD, Sadani M, Shetty A, et al. Linezolid resistance in Mycobacterium tuberculosis isolates at a tertiary care centre in Mumbai, India. Indian J Med Res. 2021;154(1):85.","journal-title":"Indian J Med Res"},{"issue":"2","key":"3474_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/ijms22020735","volume":"22","author":"A Allu\u00e9-Guardia","year":"2021","unstructured":"Allu\u00e9-Guardia A, Saranathan R, Chan J, Torrelles JB. Mycobacteriophages as potential therapeutic agents against drug-resistant tuberculosis. Int J Mol Sci. 2021;22(2):735.","journal-title":"Int J Mol Sci"},{"key":"3474_CR15","doi-asserted-by":"publisher","unstructured":"Hatfull GF, Mycobacteriophages. Microbiol Spectr. 2018;6(5). https:\/\/doi.org\/10.1128\/microbiolspec.gpp3-0026-2018.","DOI":"10.1128\/microbiolspec.gpp3-0026-2018"},{"key":"3474_CR16","doi-asserted-by":"publisher","unstructured":"Guerrero-Bustamante CA, Dedrick RM, Garlena RA, Russell DA, Hatfull GF. Toward a phage cocktail for tuberculosis: susceptibility and Tuberculocidal Action of mycobacteriophages against Diverse Mycobacterium tuberculosis strains. mBio. 2021;12(3). https:\/\/doi.org\/10.1128\/mbio.00973.","DOI":"10.1128\/mbio.00973"},{"issue":"4","key":"3474_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.coviro.2011.06.009","volume":"1","author":"GF Hatfull","year":"2011","unstructured":"Hatfull GF, Hendrix RW. Bacteriophages and their genomes. Curr Opin Virol. 2011;1(4):298\u2013303.","journal-title":"Curr Opin Virol"},{"issue":"2","key":"3474_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2012.09.026","volume":"434","author":"D Jacobs-Sera","year":"2012","unstructured":"Jacobs-Sera D, Marinelli L, Bowman C, Broussard G, Guerrero C, Boyle M, et al. On the nature of mycobacteriophage diversity and host preference. Virology. 2012;434(2):187\u2013201.","journal-title":"Virology"},{"issue":"10","key":"3474_CR19","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1007\/s11095-017-2213-4","volume":"34","author":"NB Carrigy","year":"2017","unstructured":"Carrigy NB, Chang RY, Leung SSY, Harrison M, Petrova Z, Pope WH, et al. Anti-tuberculosis bacteriophage D29 delivery with a vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler. Pharm Res. 2017;34(10):2084\u201396.","journal-title":"Pharm Res"},{"issue":"12","key":"3474_CR20","doi-asserted-by":"publisher","first-page":"e00871","DOI":"10.1128\/AAC.00871-19","volume":"63","author":"NB Carrigy","year":"2019","unstructured":"Carrigy NB, Larsen SE, Reese V, Pecor T, Harrison M, Kuehl PJ, et al. Prophylaxis of Mycobacterium tuberculosis H37Rv infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29. Antimicrob Agents Chemother. 2019;63(12):e00871\u201319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3474_CR21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/343812","volume":"186","author":"L Broxmeyer","year":"2002","unstructured":"Broxmeyer L, Sosnowska D, Miltner E, Chac\u00f3n O, Wagner D, McGarvey J, et al. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a Mycobacteriophage delivered by a nonvirulent Mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis. 2002;186(8):1155\u201360.","journal-title":"J Infect Dis"},{"issue":"1","key":"3474_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-024-06006-x","volume":"7","author":"F Yang","year":"2024","unstructured":"Yang F, Labani-Motlagh A, Bohorquez JA, Moreira JD, Ansari D, Patel S, et al. Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice. Commun Biol. 2024;7(1):1\u201313.","journal-title":"Commun Biol"},{"issue":"5","key":"3474_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730\u20133.","journal-title":"Nat Med"},{"issue":"11","key":"3474_CR24","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","volume":"185","author":"JA Nick","year":"2022","unstructured":"Nick JA, Dedrick RM, Gray AL, Vladar EK, Smith BE, Freeman KG, et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022;185(11):1860\u2013e187412.","journal-title":"Cell"},{"issue":"7","key":"3474_CR25","doi-asserted-by":"publisher","first-page":"ofac194","DOI":"10.1093\/ofid\/ofac194","volume":"9","author":"RM Dedrick","year":"2022","unstructured":"Dedrick RM, Freeman KG, Nguyen JA, Bahadirli-Talbott A, Cardin ME, Cristinziano M, et al. Nebulized bacteriophage in a patient with refractory Mycobacterium abscessus lung disease. Open Forum Infect Dis. 2022;9(7):ofac194.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"3474_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2023","unstructured":"Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, et al. Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin Infect Dis. 2023;76(1):103\u201312.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3474_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/imr.12252","volume":"264","author":"A Lenaerts","year":"2015","unstructured":"Lenaerts A, Barry CE, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 2015;264(1):288\u2013307.","journal-title":"Immunol Rev"},{"issue":"3","key":"3474_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/ijms17030131","volume":"17","author":"VC Korb","year":"2016","unstructured":"Korb VC, Chuturgoon AA, Moodley D. Mycobacterium tuberculosis: manipulator of protective immunity. Int J Mol Sci. 2016;17(3):131.","journal-title":"Int J Mol Sci"},{"key":"3474_CR29","doi-asserted-by":"publisher","unstructured":"Kalapala YC, Sharma PR, Agarwal R. Antimycobacterial Potential of Mycobacteriophage Under Disease-Mimicking Conditions. Front Microbiol [Internet]. 2020 [cited 2023 Jun 27];11. https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fmicb.2020.583661","DOI":"10.3389\/fmicb.2020.583661"},{"key":"3474_CR30","first-page":"145","volume":"101","author":"GJ Sarkis","year":"1998","unstructured":"Sarkis GJ, Hatfull GF, Mycobacteriophages. Methods Mol Biol Clifton NJ. 1998;101:145\u201373.","journal-title":"Methods Mol Biol Clifton NJ"},{"issue":"50","key":"3474_CR31","doi-asserted-by":"publisher","first-page":"12519","DOI":"10.1002\/anie.201206749","volume":"51","author":"E Kuru","year":"2012","unstructured":"Kuru E, Hughes HV, Brown PJ, Hall E, Tekkam S, Cava F, et al. In situ probing of newly synthesized Peptidoglycan in live Bacteria with fluorescent D-Amino acids. Angew Chem Int Ed. 2012;51(50):12519\u201323.","journal-title":"Angew Chem Int Ed"},{"key":"3474_CR32","doi-asserted-by":"crossref","unstructured":"Baranowski C, Welsh MA, Sham LT, Eskandarian HA, Lim HC, Kieser KJ et al. Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape. Garrett WS, Kana BD, Arthur M, editors. eLife. 2018;7:e37516.","DOI":"10.7554\/eLife.37516"},{"issue":"1","key":"3474_CR33","doi-asserted-by":"publisher","first-page":"11392","DOI":"10.1038\/ncomms11392","volume":"7","author":"A Trivedi","year":"2016","unstructured":"Trivedi A, Mavi PS, Bhatt D, Kumar A. Thiol reductive stress induces cellulose-anchored biofilm formation in Mycobacterium tuberculosis. Nat Commun. 2016;7(1):11392.","journal-title":"Nat Commun"},{"issue":"32","key":"3474_CR34","doi-asserted-by":"publisher","first-page":"e2024571118","DOI":"10.1073\/pnas.2024571118","volume":"118","author":"A Gouzy","year":"2021","unstructured":"Gouzy A, Healy C, Black KA, Rhee KY, Ehrt S. Growth of Mycobacterium tuberculosis at acidic pH depends on lipid assimilation and is accompanied by reduced GAPDH activity. Proc Natl Acad Sci. 2021;118(32):e2024571118.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"3474_CR35","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2116\/analsci.20.1153","volume":"20","author":"M Sumitani","year":"2004","unstructured":"Sumitani M, Takagi S, Tanamura Y, Inoue H. Oxygen Indicator Composed of an Organic\/Inorganic hybrid compound of Methylene Blue, reductant, surfactant and Saponite. Anal Sci. 2004;20(8):1153\u20137.","journal-title":"Anal Sci"},{"issue":"38","key":"3474_CR36","doi-asserted-by":"publisher","first-page":"40174","DOI":"10.1074\/jbc.M406796200","volume":"279","author":"HIM Boshoff","year":"2004","unstructured":"Boshoff HIM, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: NOVEL INSIGHTS INTO DRUG MECHANISMS OF ACTION *. J Biol Chem. 2004;279(38):40174\u201384.","journal-title":"J Biol Chem"},{"issue":"3","key":"3474_CR37","doi-asserted-by":"publisher","first-page":"e00938","DOI":"10.1128\/mBio.00938-18","volume":"9","author":"C Vilch\u00e8ze","year":"2018","unstructured":"Vilch\u00e8ze C, Copeland J, Keiser TL, Weisbrod T, Washington J, Jain P, et al. Rational design of Biosafety Level 2-Approved, Multidrug-resistant strains of Mycobacterium tuberculosis through Nutrient Auxotrophy. mBio. 2018;9(3):e00938\u201318.","journal-title":"mBio"},{"issue":"1","key":"3474_CR38","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41467-021-21748-6","volume":"12","author":"P Chakraborty","year":"2021","unstructured":"Chakraborty P, Bajeli S, Kaushal D, Radotra BD, Kumar A. Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis. Nat Commun. 2021;12(1):1606.","journal-title":"Nat Commun"},{"issue":"5","key":"3474_CR39","doi-asserted-by":"publisher","first-page":"e0259480","DOI":"10.1371\/journal.pone.0259480","volume":"17","author":"F Calcuttawala","year":"2022","unstructured":"Calcuttawala F, Shaw R, Sarbajna A, Dutta M, Sinha S, Gupta SKD. Apoptosis like symptoms associated with abortive infection of Mycobacterium smegmatis by mycobacteriophage D29. PLoS ONE. 2022;17(5):e0259480.","journal-title":"PLoS ONE"},{"issue":"1","key":"3474_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4161\/bact.1.1.13980","volume":"1","author":"ST Abedon","year":"2011","unstructured":"Abedon ST. Lysis from without. Bacteriophage. 2011;1(1):46\u20139.","journal-title":"Bacteriophage"},{"key":"3474_CR41","doi-asserted-by":"publisher","first-page":"101574","DOI":"10.1016\/j.cimid.2020.101574","volume":"74","author":"JL Khawbung","year":"2021","unstructured":"Khawbung JL, Nath D, Chakraborty S. Drug resistant tuberculosis: a review. Comp Immunol Microbiol Infect Dis. 2021;74:101574.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"3474_CR42","first-page":"9","volume":"12","author":"A Singh","year":"2020","unstructured":"Singh A, Prasad R, Balasubramanian V, Gupta N. Drug-resistant tuberculosis and HIV infection: current perspectives. HIVAIDS Auckl NZ. 2020;12:9\u201331.","journal-title":"HIVAIDS Auckl NZ"},{"issue":"1","key":"3474_CR43","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1038\/s41467-022-29689-4","volume":"13","author":"JS Little","year":"2022","unstructured":"Little JS, Dedrick RM, Freeman KG, Cristinziano M, Smith BE, Benson CA, et al. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nat Commun. 2022;13(1):2313.","journal-title":"Nat Commun"},{"issue":"12","key":"3474_CR44","doi-asserted-by":"publisher","first-page":"e1000767","DOI":"10.1371\/journal.pgen.1000767","volume":"5","author":"HR Ramage","year":"2009","unstructured":"Ramage HR, Connolly LE, Cox JS. Comprehensive Functional Analysis of Mycobacterium tuberculosis Toxin-Antitoxin systems: implications for Pathogenesis, stress responses, and evolution. PLoS Genet. 2009;5(12):e1000767.","journal-title":"PLoS Genet"},{"issue":"1","key":"3474_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/ciy947","volume":"69","author":"L El Haddad","year":"2019","unstructured":"El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF. A systematic and critical review of bacteriophage therapy against Multidrug-resistant ESKAPE organisms in humans. Clin Infect Dis. 2019;69(1):167\u201378.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"3474_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/v10070351","volume":"10","author":"F Oechslin","year":"2018","unstructured":"Oechslin F. Resistance Development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018;10(7):351.","journal-title":"Viruses"},{"issue":"1","key":"3474_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000519870","volume":"101","author":"AH Diacon","year":"2022","unstructured":"Diacon AH, Guerrero-Bustamante CA, Rosenkranz B, Rubio Pomar FJ, Vanker N, Hatfull GF. Mycobacteriophages to treat tuberculosis: dream or Delusion? Respiration. 2022;101(1):1\u201315.","journal-title":"Respiration"},{"issue":"1","key":"3474_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-micro-020722-013730","volume":"76","author":"M LeRoux","year":"2022","unstructured":"LeRoux M, Laub MT. Toxin-antitoxin systems as Phage Defense Elements. Annu Rev Microbiol. 2022;76(1):21\u201343.","journal-title":"Annu Rev Microbiol"},{"issue":"10","key":"3474_CR49","doi-asserted-by":"publisher","first-page":"e78543","DOI":"10.1371\/journal.pone.0078543","volume":"8","author":"S Fischer","year":"2013","unstructured":"Fischer S, Kittler S, Klein G, Gl\u00fcnder G. Impact of a single phage and a phage cocktail application in broilers on reduction of Campylobacter jejuni and development of resistance. PLoS ONE. 2013;8(10):e78543.","journal-title":"PLoS ONE"},{"key":"3474_CR50","doi-asserted-by":"publisher","unstructured":"Yang Y, Shen W, Zhong Q, Chen Q, He X, Baker JL et al. Development of a Bacteriophage Cocktail to Constrain the Emergence of Phage-Resistant Pseudomonas aeruginosa. Front Microbiol [Internet]. 2020 [cited 2024 Feb 8];11. https:\/\/www.frontiersin.org\/journals\/microbiology\/articles\/https:\/\/doi.org\/10.3389\/fmicb.2020.00327","DOI":"10.3389\/fmicb.2020.00327"},{"issue":"5","key":"3474_CR51","doi-asserted-by":"publisher","first-page":"e0291422","DOI":"10.1128\/spectrum.02914-22","volume":"10","author":"D Gao","year":"2022","unstructured":"Gao D, Ji H, Wang L, Li X, Hu D, Zhao J, et al. Fitness Trade-Offs in Phage Cocktail-Resistant Salmonella enterica Serovar Enteritidis results in increased antibiotic susceptibility and reduced virulence. Microbiol Spectr. 2022;10(5):e0291422.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"3474_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/eva.13518","volume":"16","author":"JM Borin","year":"2022","unstructured":"Borin JM, Lee JJ, Gerbino KR, Meyer JR. Comparison of bacterial suppression by phage cocktails, dual-receptor generalists, and coevolutionarily trained phages. Evol Appl. 2022;16(1):152\u201362.","journal-title":"Evol Appl"},{"key":"3474_CR53","doi-asserted-by":"publisher","unstructured":"Ehlers S, Schaible UE. The Granuloma in Tuberculosis: Dynamics of a Host\u2013Pathogen Collusion. Front Immunol [Internet]. 2013 Jan 7 [cited 2024 Jul 6];3. https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2012.00411\/full","DOI":"10.3389\/fimmu.2012.00411\/full"},{"issue":"1","key":"3474_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/mdr.2006.12.1","volume":"12","author":"L Danelishvili","year":"2006","unstructured":"Danelishvili L, Young LS, Bermudez LE. In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium. Microb Drug Resist Larchmt N. 2006;12(1):1\u20136.","journal-title":"Microb Drug Resist Larchmt N"},{"issue":"10","key":"3474_CR55","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nm.2420","volume":"17","author":"KA Sweeney","year":"2011","unstructured":"Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, Henao-Tamayo M, et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med. 2011;17(10):1261\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"3474_CR56","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1517\/17425247.2015.1043125","volume":"12","author":"A Nieth","year":"2015","unstructured":"Nieth A, Verseux C, Barnert S, S\u00fcss R, R\u00f6mer W. A first step toward liposome-mediated intracellular bacteriophage therapy. Expert Opin Drug Deliv. 2015;12(9):1411\u201324.","journal-title":"Expert Opin Drug Deliv"},{"issue":"13","key":"3474_CR57","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.7150\/ijbs.60551","volume":"17","author":"X Li","year":"2021","unstructured":"Li X, He Y, Wang Z, Wei J, Hu T, Si J, et al. A combination therapy of phages and antibiotics: two is better than one. Int J Biol Sci. 2021;17(13):3573\u201382.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"3474_CR58","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","volume":"27","author":"RM Dedrick","year":"2021","unstructured":"Dedrick RM, Freeman KG, Nguyen JA, Bahadirli-Talbott A, Smith BE, Wu AE, et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat Med. 2021;27(8):1357\u201361.","journal-title":"Nat Med"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-024-03474-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-024-03474-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-024-03474-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T04:03:28Z","timestamp":1725422608000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-024-03474-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1186\/s12866-024-03474-3","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments involving <i>Mycobacterium tuberculosis<\/i> were performed in a Biosafety level-3 facility (Institutional Biosafety Committee approval: IBSC\/IISc\/RA\/20\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}